miRecule Inc. is a biotechnology company which develops highly tissue-targeted RNA therapeutics for neuromuscular diseases and oncology indications. Their proprietary DREAmiR™ platform identifies genetic changes causing diseases which in turn allows the company to generate novel antibody RNA conjugate therapeutics in targeted patient populations. They are developing first-in-class therapies, with lead programs in Facioscapulohumeral Muscular Dystrophy (FSHD) and Head and Neck Cancer. They have partnered their FSHD program with Sanofi to pioneer innovative approaches targeting the underlying cause of FSHD in muscle tissue. They have additional programs in Glycogen Storage Diseases and other Muscular Dystrophies.